HC Wainwright Reaffirms “Buy” Rating for Inovio Pharmaceuticals, Inc. (INO)

HC Wainwright reissued their buy rating on shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) in a research note published on Tuesday morning. They currently have a $13.00 price objective on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the stock. Piper Jaffray Companies raised shares of Inovio Pharmaceuticals from a neutral rating to an overweight rating and set a $14.00 price target for the company in a research report on Thursday, June 8th. Maxim Group reissued a buy rating and issued a $12.00 price target on shares of Inovio Pharmaceuticals in a research report on Tuesday. Zacks Investment Research raised shares of Inovio Pharmaceuticals from a hold rating to a buy rating and set a $8.75 price target for the company in a research report on Tuesday, July 11th. BidaskClub raised shares of Inovio Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, September 9th. Finally, Aegis increased their price target on shares of Inovio Pharmaceuticals from $11.00 to $14.00 and gave the stock a buy rating in a research report on Thursday, May 25th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $19.80.

Inovio Pharmaceuticals (NASDAQ:INO) opened at 5.97 on Tuesday. The stock has a 50 day moving average of $5.70 and a 200-day moving average of $6.67. The firm’s market cap is $538.66 million. Inovio Pharmaceuticals has a 52-week low of $5.28 and a 52-week high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. The company had revenue of $20.41 million during the quarter, compared to analyst estimates of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The business’s quarterly revenue was up 229.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.26) earnings per share. On average, analysts expect that Inovio Pharmaceuticals will post ($0.92) EPS for the current year.

WARNING: “HC Wainwright Reaffirms “Buy” Rating for Inovio Pharmaceuticals, Inc. (INO)” was first reported by BBNS and is the property of of BBNS. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/markets/hc-wainwright-reaffirms-buy-rating-for-inovio-pharmaceuticals-inc-ino/1638469.html.

Institutional investors and hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN raised its position in Inovio Pharmaceuticals by 28.9% during the first quarter. Wells Fargo & Company MN now owns 124,565 shares of the biopharmaceutical company’s stock valued at $825,000 after acquiring an additional 27,898 shares in the last quarter. Vident Investment Advisory LLC raised its position in Inovio Pharmaceuticals by 20.0% during the first quarter. Vident Investment Advisory LLC now owns 127,375 shares of the biopharmaceutical company’s stock valued at $843,000 after acquiring an additional 21,228 shares in the last quarter. Bank of New York Mellon Corp raised its position in Inovio Pharmaceuticals by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock valued at $2,266,000 after acquiring an additional 11,765 shares in the last quarter. Vanguard Group Inc. raised its position in Inovio Pharmaceuticals by 7.9% during the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock valued at $20,510,000 after acquiring an additional 226,861 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its position in Inovio Pharmaceuticals by 8.5% during the first quarter. Metropolitan Life Insurance Co. NY now owns 51,573 shares of the biopharmaceutical company’s stock valued at $341,000 after acquiring an additional 4,020 shares in the last quarter. 24.83% of the stock is currently owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster


Leave a Reply

 
© 2006-2017 BBNS.